Compare ELE & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELE | MNKD |
|---|---|---|
| Founded | N/A | 1991 |
| Country | Canada | United States |
| Employees | 39 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2004 |
| Metric | ELE | MNKD |
|---|---|---|
| Price | $15.70 | $4.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $32.50 | $8.69 |
| AVG Volume (30 Days) | 496.2K | ★ 4.7M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $109.25 | $35.81 |
| Revenue Next Year | $16.14 | $11.89 |
| P/E Ratio | $255.64 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $14.01 | $2.23 |
| 52 Week High | $26.96 | $6.51 |
| Indicator | ELE | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 54.62 |
| Support Level | $14.43 | $3.81 |
| Resistance Level | $17.83 | $4.29 |
| Average True Range (ATR) | 0.78 | 0.22 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 54.64 | 56.77 |
Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments. It is the result of the strategic merger of Elemental Altus Royalties and EMX Royalty Corporation together creating a mid-tier gold-focused royalty company with the scale, diversification, and cash flow. Geographically, the company generates revenue from North America, South America, Europe, Australia and Africa.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.